Literature DB >> 21198355

Toll-like receptors as interferon-regulated genes and their role in disease.

Jing Jing Khoo1, Sam Forster, Ashley Mansell.   

Abstract

The Toll-like receptors (TLRs) are innate sensors that recognize both microbial and endogenous ligands, initiating the host defense response. TLRs initiate the potent proinflammatory response to infection, are the target for adjuvants, and are essential for the establishment and maturation of adaptive immunity. As such they have been the interest of widespread research and the target of therapeutic intervention on multiple diseases. It has become apparent that expression of a subset of TLRs (TLR1, TLR2, TLR3, TLR5, and TLR7) is induced by Type I interferons (IFN). The role and impact of IFN expression on TLR responses is therefore critical in understanding the role of TLRs in disease, particularly as IFN itself is a downstream gene induced by specific TLRs. In this review we discuss the function and role of IFN-regulated TLRs in disease and how the role of IFN may impact upon TLR induction of the immune response in diseases, particularly in mouse models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21198355     DOI: 10.1089/jir.2010.0095

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  21 in total

Review 1.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Authors:  Martina Musella; Gwenola Manic; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

Review 2.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 3.  Innate immune signalling at the intestinal epithelium in homeostasis and disease.

Authors:  Johanna Pott; Mathias Hornef
Journal:  EMBO Rep       Date:  2012-07-17       Impact factor: 8.807

Review 4.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

5.  Two microRNAs encoded within the bovine herpesvirus 1 latency-related gene promote cell survival by interacting with RIG-I and stimulating NF-κB-dependent transcription and beta interferon signaling pathways.

Authors:  Leticia Frizzo da Silva; Clinton Jones
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

6.  Gene expression based evidence of innate immune response activation in the epithelium with oral lichen planus.

Authors:  Guy R Adami; Alexander C F Yeung; Grant Stucki; Antonia Kolokythas; Herve Y Sroussi; Robert J Cabay; Igor Kuzin; Joel L Schwartz
Journal:  Arch Oral Biol       Date:  2014-01-04       Impact factor: 2.633

7.  Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment.

Authors:  Correne A DeCarlo; Bruce Rosa; Robert Jackson; Sarah Niccoli; Nicholas G Escott; Ingeborg Zehbe
Journal:  Clin Dev Immunol       Date:  2011-10-13

8.  Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling.

Authors:  Gavin C K W Koh; M Fernanda Schreiber; Ruben Bautista; Rapeephan R Maude; Susanna Dunachie; Direk Limmathurotsakul; Nicholas P J Day; Gordon Dougan; Sharon J Peacock
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

9.  Gene regulatory network analysis supports inflammation as a key neurodegeneration process in prion disease.

Authors:  Isaac Crespo; Kirsten Roomp; Wiktor Jurkowski; Hiroaki Kitano; Antonio del Sol
Journal:  BMC Syst Biol       Date:  2012-10-15

Review 10.  Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles.

Authors:  Kenneth C McCullough; Panagiota Milona; Lisa Thomann-Harwood; Thomas Démoulins; Pavlos Englezou; Rolf Suter; Nicolas Ruggli
Journal:  Vaccines (Basel)       Date:  2014-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.